NAMS Revenue third quarter 2026 Y/Y Growth Comment
Newamsterdam Pharma Company N v achieved in the third quarter 2026, above Company average Revenue surge of 5375.43% year on year, to $ 19.16 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Newamsterdam Pharma Company N V ' s Revenue doubling of 5375.43% ranks overall at the positon no. 473 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Newamsterdam Pharma N V 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
9400 %
836.6 %
-98.18 %
(Mar 31 2026)
NAMS's III. Quarter Q/Q Revenue Comment
Newamsterdam Pharma Company N v achieved in the III. Quarter 2026 below company average Revenue doubling of 417.95% quarter on quarter, to $ 19.16 millions.
Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -98.17% growth in the III. Quarter a year ago
Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Newamsterdam Pharma N V 's Revenue growth quarter on quarter, overall rank is 488.
Newamsterdam Pharma Company N v achieved in the III. Quarter 2026 below company average Revenue doubling of 417.95% quarter on quarter, to $ 19.16 millions.
III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -98.17% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Newamsterdam Pharma N V 's Revenue growth quarter on quarter, overall rank is 488.
Newamsterdam Pharma N V 's 12 Months Revenue Growth Year on Year
Newamsterdam Pharma N V 's cumulative 12 months Revenue continue to drop, but on the faster rate at -88.87% year on year, at Jun 30 2026 compare to the -52.13% decrease at Mar 31 2026. If the Newamsterdam Pharma N V 's fiscal year would end at Jun 30 2026, annual Revenue would be $7 millions.
Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 35, from total ranking in previous quarter at 2931.
Newamsterdam Pharma N V 's cumulative 12 months Revenue continue to drop, but on the faster rate at -88.87% year on year, at Jun 30 2026 compare to the -52.13% decrease at Mar 31 2026. If the Newamsterdam Pharma N V 's fiscal year would end at Jun 30 2026, annual Revenue would be $7 millions.
Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 35, from total ranking in previous quarter at 2931.
About Newamsterdam Pharma N V Revenue Growth Rates (NAMS), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Newamsterdam Pharma Co N V
(CIK 1936258).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
5,723.64%